pirenzepine has been researched along with Autoimmune Diabetes in 32 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our observations of an increased glucose requirement during the clamp as well as a decrease in haemoglobin A1c demonstrate improved insulin sensitivity in the adolescent girls with diabetes following pirenzepine therapy." | 5.10 | Insulin sensitivity and lipolysis in adolescent girls with poorly controlled type 1 diabetes: effect of anticholinergic treatment. ( Brismar, K; Gustafsson, J; Halldin, MU; Tuvemo, T, 2002) |
| "The aims of the present study were to compare nocturnal growth hormone (GH) secretion, insulin requirements and insulin sensitivity on two occasions in six adolescent girls with type 1 diabetes when the GH secretion was reduced one night by an oral dose of 100 mg of pirenzepine at bedtime." | 5.08 | Reduced growth hormone secretion improves insulin sensitivity in adolescent girls with type 1 diabetes. ( Aman, J; Hagenäs, L; Jones, I; Karlsson, I; Kroon, M, 1996) |
| "Twelve male subjects with IDDM and no clinical evidence of complications were selected on the basis of HbA1 levels to provide a wide range of metabolic control." | 2.68 | Effects of cholinergic modulation on serum insulin-like growth factor-I and its binding proteins in normal and diabetic subjects. ( Ismail, IS; Miell, JP; Peters, JR; Scanlon, MF, 1995) |
| "Thirteen male subjects with IDDM and no clinical evidence of complications were selected based on HbA1 levels to provide a wide range of metabolic control." | 2.67 | Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback. ( Ismail, IS; Peters, JR; Scanlon, MF, 1993) |
| "Increased GH levels in Type I diabetes mellitus have been implicated in the pathogenesis of metabolic complications such as the so-called dawn phenomenon." | 2.66 | The effect of pirenzepine on growth hormone and blood glucose levels in type I diabetes mellitus. A controlled study in patients on basal bolus insulin treatment. ( Pietschmann, P; Schernthaner, G, 1988) |
| "However, hyperglycemia (especially postprandial hyperglycemia) and hypoglicemia continue to be problematic in the management of type 1 diabetes." | 2.44 | [Adjunctive therapies to glycaemic control of type 1 diabetes mellitus]. ( Gabbay, Mde A, 2008) |
| " Therefore, we investigated in a dose-response fashion the inhibitory effect of the muscarinic cholinergic receptor antagonist pirenzepine on the GH responses to arginine infusion (30 g infused intravenously (IV) in 30 minutes), exercise (bicycle ergometer test at an intensity of 75 W for 30 minutes), or 1-44 GH-releasing hormone (GHRH) (1 microgram/kg in an IV bolus)." | 1.28 | Reduced sensitivity to pirenzepine-induced blockade of growth hormone responses to arginine, exercise, and growth hormone-releasing hormone in type I diabetic subjects. ( Bianconi, L; Capretti, L; Coiro, V; Davoli, C; Fagnoni, F; Gardini, E; Maffei, ML; Passeri, M; Speroni, G; Volpi, R, 1990) |
| "Pretreatment with pirenzepine (40 mg given iv 10 min before TRH) suppressed the TRH-induced GH rise." | 1.27 | The growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics involves a cholinergic mechanism. ( Butturini, U; Capretti, L; Chiodera, P; Coiro, V; Muzzetto, P; Speroni, G; Volpi, R, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (25.00) | 18.7374 |
| 1990's | 17 (53.13) | 18.2507 |
| 2000's | 7 (21.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kozian, R | 1 |
| Halldin, MU | 2 |
| Brismar, K | 2 |
| Tuvemo, T | 2 |
| Gustafsson, J | 2 |
| Tavakoli, SA | 1 |
| Arguisola, MS | 1 |
| Gabbay, Mde A | 1 |
| Chiodera, P | 2 |
| Coiro, V | 3 |
| Speroni, G | 3 |
| Capretti, L | 3 |
| Muzzetto, P | 1 |
| Volpi, R | 3 |
| Butturini, U | 1 |
| Ismail, IS | 2 |
| Miell, JP | 1 |
| Scanlon, MF | 4 |
| Peters, JR | 4 |
| Benitez del Castillo, JM | 2 |
| Ruibal, JL | 1 |
| Reverte, F | 1 |
| Seara, G | 1 |
| Fernandez, PC | 1 |
| Duran, S | 1 |
| Casado, E | 1 |
| Garcia Sanchez, J | 2 |
| Ruibal Francisco, JL | 3 |
| Seara Aguilar, G | 3 |
| Fernández Vila, PC | 1 |
| Fernández Méndez, M | 3 |
| Reverte Blanc, F | 3 |
| Casado de Frías, E | 3 |
| Krassowski, J | 2 |
| Szulc, P | 1 |
| Makowska, A | 1 |
| Godziejewska, M | 1 |
| Jeske, W | 2 |
| Zgliczynski, S | 2 |
| Edge, JA | 3 |
| Harris, DA | 1 |
| Phillips, PE | 1 |
| Pal, BR | 2 |
| Matthews, DR | 3 |
| Dunger, DB | 3 |
| Mullis, PE | 1 |
| Hindmarsh, PC | 1 |
| Aman, J | 2 |
| Kroon, M | 1 |
| Karlsson, I | 1 |
| Jones, I | 2 |
| Hagenäs, L | 1 |
| Goñi, MJ | 1 |
| Monreal, M | 1 |
| Goñi, F | 1 |
| Sopena, M | 1 |
| Gil, MJ | 1 |
| Moncada, E | 1 |
| Salvador, J | 1 |
| Fertig, MK | 1 |
| Brooks, VG | 1 |
| Shelton, PS | 1 |
| English, CW | 1 |
| Snoddgrass, PL | 1 |
| Labbate, LA | 1 |
| Van Meter, SA | 1 |
| Seaburg, H | 1 |
| McLendon, B | 1 |
| Doraiswamy, PM | 1 |
| Sernyak, MJ | 1 |
| Leslie, DL | 1 |
| Alarcon, RD | 1 |
| Losonczy, MF | 1 |
| Rosenheck, R | 1 |
| Rogala, H | 1 |
| Noya Beiroa, E | 2 |
| Lara Herrero, E | 1 |
| Cabranes Díaz, JA | 2 |
| Valor García, S | 1 |
| Mimura, A | 1 |
| Kageyama, S | 1 |
| Itoh, K | 1 |
| Miura, J | 1 |
| Kurata, H | 1 |
| Yokoyama, J | 1 |
| Ikeda, Y | 1 |
| Passeri, M | 1 |
| Gardini, E | 2 |
| Davoli, C | 1 |
| Maffei, ML | 1 |
| Fagnoni, F | 1 |
| Bianconi, L | 1 |
| Castelli, A | 1 |
| Mosti, A | 1 |
| Marchesi, C | 1 |
| Rossi, G | 1 |
| Atiea, JA | 1 |
| Creagh, F | 1 |
| Page, M | 1 |
| Owens, DR | 1 |
| Martina, V | 2 |
| Maccario, M | 2 |
| Tagliabue, M | 2 |
| Corno, M | 1 |
| Camanni, F | 2 |
| Pietschmann, P | 1 |
| Schernthaner, G | 1 |
| Arends, J | 1 |
| Wagner, ML | 1 |
| Willms, BL | 1 |
| Page, MD | 1 |
| Koppeschaar, HP | 1 |
| Dieguez, C | 1 |
| Gibbs, JT | 1 |
| Hall, R | 1 |
| Bertagna, A | 1 |
| Ghigo, E | 1 |
| Massara, F | 1 |
2 reviews available for pirenzepine and Autoimmune Diabetes
| Article | Year |
|---|---|
[Adjunctive therapies to glycaemic control of type 1 diabetes mellitus].
Topics: Acarbose; Amyloid; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Gastrointest | 2008 |
[Nocturnal use of pirenzepine by a group of insulin dependent juvenile diabetics].
Topics: Administration, Oral; Adolescent; Child; Diabetes Mellitus, Type 1; Drug Evaluation; Female; Growth | 1992 |
10 trials available for pirenzepine and Autoimmune Diabetes
| Article | Year |
|---|---|
Insulin sensitivity and lipolysis in adolescent girls with poorly controlled type 1 diabetes: effect of anticholinergic treatment.
Topics: Adolescent; Blood Glucose; Cholinergic Antagonists; Diabetes Mellitus, Type 1; Female; Glycated Hemo | 2002 |
Effects of cholinergic modulation on serum insulin-like growth factor-I and its binding proteins in normal and diabetic subjects.
Topics: Blood Glucose; Carrier Proteins; Diabetes Mellitus, Type 1; Growth Hormone-Releasing Hormone; Humans | 1995 |
Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
Topics: Adult; Blood Glucose; Cholinesterase Inhibitors; Diabetes Mellitus, Type 1; Feedback; Growth Hormone | 1993 |
Reduced growth hormone secretion improves insulin sensitivity in adolescent girls with type 1 diabetes.
Topics: Administration, Oral; Adolescent; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Dose-R | 1996 |
Effects of cholinergic blockade on nocturnal thyrotropin and growth hormone (GH) secretion in type I diabetes mellitus: further evidence supporting somatostatin's involvement in GH suppression.
Topics: Administration, Oral; Adult; Blood Glucose; Circadian Rhythm; Cohort Studies; Diabetes Mellitus, Typ | 1997 |
Anticholinergic treatment improves glycaemic control in adolescent girls with insulin-dependent diabetes mellitus.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus, Type 1; Female; Growth Hormone; Hemoglobins; Humans; I | 2001 |
[Nocturnal use of pirenzepine by a group of insulin dependent juvenile diabetics].
Topics: Administration, Oral; Adolescent; Child; Diabetes Mellitus, Type 1; Drug Evaluation; Female; Growth | 1992 |
The dawn phenomenon is related to overnight growth hormone release in adolescent diabetics.
Topics: Adolescent; Child; Circadian Rhythm; Depression, Chemical; Diabetes Mellitus, Type 1; Female; Glucos | 1990 |
The effect of pirenzepine on growth hormone and blood glucose levels in type I diabetes mellitus. A controlled study in patients on basal bolus insulin treatment.
Topics: Administration, Oral; Adult; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 1; Fem | 1988 |
Cholinergic muscarinic receptor blockade with pirenzepine abolishes slow wave sleep-related growth hormone release in young patients with insulin-dependent diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Female; Growth Hormone; Humans; Male; Muscarinic Antagonists; Pire | 1987 |
21 other studies available for pirenzepine and Autoimmune Diabetes
| Article | Year |
|---|---|
[Olanzapine-induced diabetes mellitus].
Topics: Adult; Benzodiazepines; Body Weight; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Dose-Response | 2002 |
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepi | 2003 |
The growth hormone response to thyrotropin-releasing hormone in insulin-dependent diabetics involves a cholinergic mechanism.
Topics: Adult; Benzodiazepinones; Diabetes Mellitus, Type 1; Growth Hormone; Humans; Male; Middle Aged; Para | 1984 |
[Inhibition of growth hormone in insulin-dependent diabetics after oral administration of pirenzepine. Fluorophotometric study of the vitreous body].
Topics: Administration, Oral; Adolescent; Blood-Retinal Barrier; Diabetes Mellitus, Type 1; Female; Fluoroph | 1994 |
[Vitreous fluorophotometry and nocturnal GH secretion in young insulin-dependent diabetics treated with oral pirenzepine].
Topics: Administration, Oral; Adolescent; Child; Circadian Rhythm; Diabetes Mellitus, Type 1; Diabetic Retin | 1993 |
Short term pirenzepine treatment is ineffective in suppressing 24-h growth hormone secretion in type 1 diabetes mellitus.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Growth Hormone; Growth Hormone-Releasing Ho | 1993 |
Evidence for a role for insulin and growth hormone in overnight regulation of 3-hydroxybutyrate in normal and diabetic adolescents.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adolescent; Adult; Age Factors; C-Peptide; Child; Circadian Rh | 1993 |
The frequency and amplitude of growth hormone secretory episodes as determined by deconvolution analysis are increased in adolescents with insulin dependent diabetes mellitus and are unaffected by short-term euglycaemia.
Topics: Adolescent; Adult; Child; Circadian Rhythm; Diabetes Mellitus, Type 1; Female; Glucose Clamp Techniq | 1993 |
Hyperglycemia associated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1998 |
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dyskinesia, Drug-Induc | 1999 |
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dose-Response Relationship, | 2001 |
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Benzodiazepines; Clozapi | 2002 |
[Inhibition of growth hormone (GH) response to GHRH in diabetes mellitus type 1 after blockade of the cholinergic system with pirenzepine].
Topics: Adult; Depression, Chemical; Diabetes Mellitus, Type 1; Female; Growth Hormone; Growth Hormone-Relea | 1992 |
[Nocturnal use of pirenzepine in young insulin dependent diabetics. Results of a 6-months treatment period].
Topics: Administration, Oral; Adolescent; Child; Diabetes Mellitus, Type 1; Female; Growth Hormone; Growth H | 1992 |
[Role of growth hormone in the pathogenesis of dawn phenomenon in IDDM].
Topics: Adult; Circadian Rhythm; Diabetes Mellitus, Type 1; Growth Hormone; Humans; Hyperglycemia; Insulin I | 1992 |
Reduced sensitivity to pirenzepine-induced blockade of growth hormone responses to arginine, exercise, and growth hormone-releasing hormone in type I diabetic subjects.
Topics: Adolescent; Adult; Arginine; Blood Glucose; Child; Child, Preschool; Diabetes Mellitus, Type 1; Exer | 1990 |
Simultaneous inhibition by pirenzepine of the GH responses to GnRH and TRH in insulin-dependent diabetics and in patients with major depression.
Topics: Acetylcholine; Adult; Depression; Diabetes Mellitus, Type 1; Growth Hormone; Humans; Male; Pirenzepi | 1989 |
Early morning hyperglycemia in insulin-dependent diabetes: acute and sustained effects of cholinergic blockade.
Topics: Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1; Glucagon; Growth Hormone; Humans; | 1989 |
Chronic treatment with pirenzepine decreases growth hormone secretion in insulin-dependent diabetes mellitus.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Growth Hormone; Humans; Male; Middle Aged; | 1989 |
Cholinergic muscarinic receptor blockade suppresses arginine- and exercise-induced growth hormone secretion in type I diabetic subjects.
Topics: Adult; Arginine; Diabetes Mellitus, Type 1; Growth Hormone; Humans; Male; Middle Aged; Physical Exer | 1988 |
Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes.
Topics: Administration, Oral; Adult; Diabetes Mellitus, Type 1; Growth Hormone; Humans; Injections, Intraven | 1987 |